Natural product target identification of wheldone, a fungal metabolite, as a KIF11 inhibitor in ovarian cancer using the DiffPOP (Differential Protein Precipitation) method.

Wheldone, a fungal metabolite, was identified as a cytotoxic compound in high-grade serous ovarian cancer (HGSOC).Wheldone induced caspase 3/7-dependent apoptosis and reduced migration, invasion, and spheroid growth.Wheldone stimulated apoptosis in chemoresistant HGSOC models.Wheldone treatment caused significant downregulation of HNRNPD, a DNA repair protein, and increased DNA damage that could be blocked by N-acetyl-L-cysteine.In vivo, wheldone displayed minimal toxicity but was rapidly cleared from circulation, despite in vitro metabolic stability.Wheldone treatment in vivo did not demonstrate significant reduction in tumor burden.Therefore, in order to overcome these liabilities, it was necessary to find the protein target of wheldone so that modifications can be made to improve the drug-like characteristics of the compound.Using the drug-target interaction proteomics method, DiffPOP (differential precipitation of proteins), wheldone was found to act as an inhibitor of KIF11, a motor protein essential for mitotic spindle formation.An ATPase biochemical cell-free assay confirmed direct binding and functional inhibition of KIF11.Wheldone resulted in G2/M arrest and downstream regulation of mitotic proteins such as TPX2, AURKA, and phospho-histone H3.Proteomics after treatment of wheldone in four different HGSOC cancer cell lines all supported changes consistent with mitotic spindle assembly disruption.Further, KIF11 was one of only 13 proteins upregulated in all four cell lines treated.Overall, wheldone was found to be a fungal metabolite that inhibits KIF11 in chemoresistant ovarian cancer, with future studies needed to improve its pharmacokinetics and delivery.